Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United States
Prophylactic treatment of HAE with berotralstat was associated with significant reductions in all-cause HRU, including decreases to angioedema-related and HAE attack-related medical visits, hospitalizations, and administration of on-demand treatment.
Authors
- Douglas Johnston (ORCID: https://orcid.org/0000-0003-0440-9789)
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Sandra Nestler-Parr
- Sean D. MacKnight (ORCID: https://orcid.org/0000-0001-5032-2110)
- Lorena López-González (ORCID: https://orcid.org/0000-0002-2589-9935)
- Julien Boudreau
- Sandra C. Christiansen (ORCID: https://orcid.org/0009-0006-1576-4523)
- Bruce L. Zuraw (ORCID: https://orcid.org/0000-0003-0640-6768)
- C Spencer (ORCID: https://orcid.org/0000-0002-9611-9895)
- Patrick Gillard
Institutions
- United States Department of Veterans Affairs (US)
- University of California San Diego (US)
- BioCryst Pharmaceuticals (United States) (US)
- Group for Research in Decision Analysis (CA)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-05-30
- DOI
- https://doi.org/10.18553/jmcp.2025.31.6.578
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00